Top Page
Q-linea AB
(QLINEA)
Q-linea AB (QLINEA) vs. iShares MSCI Sweden ETF (EWD)
Q-linea AB Business Overview & Revenue Model
Q-linea AB Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.10M | 2.36M | 4.44M | 12.79M | 9.34M |
| Gross Profit | -180.02M | -11.11M | 995.00K | -21.38M | -25.03M |
| EBITDA | -160.54M | -195.40M | -210.99M | -252.69M | -218.48M |
| Net Income | -182.49M | -216.87M | -229.37M | -275.77M | -233.18M |
Balance Sheet | |||||
| Total Assets | 369.67M | 147.99M | 231.98M | 207.39M | 466.63M |
| Cash, Cash Equivalents and Short-Term Investments | 258.11M | 25.66M | 81.89M | 72.62M | 166.03M |
| Total Debt | 7.71M | 151.21M | 20.56M | 20.93M | 79.00K |
| Total Liabilities | 31.66M | 175.45M | 42.34M | 45.76M | 35.84M |
| Stockholders Equity | 338.00M | -27.46M | 189.64M | 161.63M | 430.79M |
Cash Flow | |||||
| Free Cash Flow | -169.68M | -187.49M | -236.86M | -268.11M | -267.02M |
| Operating Cash Flow | -162.12M | -182.50M | -228.52M | -250.86M | -255.05M |
| Investing Cash Flow | -7.22M | -5.04M | -7.77M | 315.25M | -23.82M |
| Financing Cash Flow | 402.12M | 131.27M | 245.41M | -6.60M | 283.81M |
Q-linea AB Technical Analysis
Q-linea AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr589.42M | -1.69 | -35.70% | ― | -18.46% | 4.90% | |
49 Neutral | kr185.11M | -3.65 | -51.35% | ― | ― | -34.02% | |
44 Neutral | kr2.84B | -5.68 | -49.96% | ― | -91.85% | -6.65% | |
43 Neutral | kr100.79M | -2.37 | -72.82% | ― | 40.91% | 57.92% | |
42 Neutral | kr409.65M | -0.91 | -108.15% | ― | 270.64% | 62.29% | |
42 Neutral | kr31.06M | -0.24 | -186.13% | ― | ― | 0.30% |
Q-linea AB Corporate Events
Q-linea AB’s nomination committee has proposed a largely unchanged board for the 2026 annual general meeting, with the addition of two new members, investment manager Öystein Engebretsen and Medistim CEO Kari Krogstad, while current director Karin Fischer has declined re-election. The committee recommends re-electing Johan Bygge as chairman and Mario Gualano as vice chairman, confirms all proposed directors as independent of management and most as independent of major shareholders, proposes reappointment of Öhrlings PricewaterhouseCoopers as auditor, and leaves board and committee fees unchanged, signaling governance continuity as the company advances its infection diagnostics strategy.
The nomination committee, chaired by Engebretsen and including several current board representatives, will publish its full rationale and detailed director information on Q-linea’s website at least three weeks before the meeting. The proposed stable governance, combined with the financial and biomedical expertise of the new nominees, is intended to support Q-linea’s efforts to strengthen its position in rapid antibiotic susceptibility testing and its broader role in addressing antimicrobial resistance in global healthcare markets.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK24.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea reported full-year 2025 net sales of SEK 11.1 million, up from SEK 2.4 million a year earlier, while narrowing its operating loss to SEK 176.7 million and strengthening its balance sheet with a nearly fully subscribed rights issue that raised about SEK 312 million. The company expanded its installed base of ASTar systems to 19 contracted instruments, with Italy emerging as a key reference market and the United States entering a commercial phase marked by the first hospital contracts, conversions from competitor platforms, and building demand ahead of an expanded ASTar test menu expected to launch in 2026. Management implemented a cost-reduction program, shifted resources from development to commercial roles, brought consumables production in-house to improve margins, and restructured the organization under a new CEO, all aimed at driving consumables-led recurring revenues, supporting global expansion and positioning Q-linea to reach breakeven by 2027.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK25.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB has signed a contract for the adoption of its ASTar® rapid antibiotic susceptibility testing system by a large independent health system in the southeastern United States, specializing in cancer and pediatric care, following an evaluation begun in 2025. The deal marks further U.S. traction for Q-linea’s flagship technology, underscoring the company’s push to expand its presence in high-acuity hospital settings where faster, more precise infection diagnostics can improve outcomes for vulnerable patient groups and support efforts against antimicrobial resistance.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK26.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea has announced a reshaping of its US commercial leadership, with VP US Commercial Operations Jim Kathrein set to step down and support a transition during the first quarter of 2026, while Ethan Suttles, currently US Director of Strategic Accounts, will assume leadership of the US sales team and report directly to CEO Stuart Gander from 1 February 2026. The company is consolidating its US-based global leadership structure by having Natalie Brown, Director Global Marketing, and Vikas Gupta, Senior Director of Clinical Affairs, report directly to the CEO as well, underscoring a sharpened focus on executing Q-linea’s commercial strategy in the key US diagnostics market and accelerating the conversion of its growing ASTar® pipeline into routine clinical use heading into 2026.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea has signed its first distribution agreement in South Asia with Genetic Trading, a leading Bangladeshi distributor, in a move that advances the company’s global expansion strategy. Genetic Trading is completing product registration in Bangladesh, after which the first ASTar instrument order will be deployed for evaluation at a major hospital, positioning Q-linea to address the region’s significant sepsis and antimicrobial resistance challenges and laying the groundwork for broader South Asian market entry targeted for 2026.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea has been selected to supply its ASTar rapid antimicrobial susceptibility testing system to several Italian laboratories to meet tender obligations following the market withdrawal of the Accelerate Pheno rapid AST system. The company is working closely with affected labs to ensure a swift transition, with customers citing ASTar’s ease of use, broad organism and antibiotic coverage, and high-throughput capabilities, and Q-linea is also assessing additional demand from former Pheno users seeking a reliable replacement solution.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB has achieved its first clinical implementations of the ASTar rapid antibiotic susceptibility testing system in the United States, with University of Iowa Health Care and a major Texas healthcare system now using the instrument. At UI Health Care, ASTar will expand statewide blood culture testing capacity, enabling faster selection of effective antibiotics for septic and other critically ill patients, and is expected to improve outcomes, reduce time to optimal therapy and streamline laboratory workflows through features such as full automation, high-throughput random-access testing, broad antibiotic panels and direct integration with Epic’s electronic medical record system, strengthening Q-linea’s foothold in the US hospital market for rapid AST solutions.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.